ClinicalTrials.gg
RecruitingNCT04216927Updated Aug 5, 2026

NO During CPB in Neonates to Reduce Risk of AKI

A Phase 3 interventional study of Nitric Oxide and Oxygen in AKI, CHD - Congenital Heart Disease and Surgery, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Open to participants aged 1 Day to 31 Days. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
1 Day to 31 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati — 4 open to participants now, 5 under way, 1 of them phase 3. Heart Defects, Congenital · Children's Hospital Medical Center, Cincinnati.

Started
2023
with 1 other
Phase 3
Only one
of the 14
Registered
9th of 14
by date

Among the 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati, this one is one of 2 that started in 2023, is the only one in phase 3, and was the 9th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

4 of the 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 1 Day to 31 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Defects, Congenital by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

Acute kidney injury (AKI) following cardiac surgery for congenital heart defects (CHD) in children affects up to 60% of high risk-patients and is a major cause of both short- and long-term morbidity and mortality. Despite effort, to date, no successful therapeutic agent has gained widespread success in preventing this postoperative decline in renal function. Nitric oxide is an intricate regulator of acute inflammation and coagulation and is a potent vasodilator. The investigators hypothesize that nitric oxide, administered during cardiopulmonary bypass (CPB), may reduce the incidence of AKI.

03

Conditions studied

  • AKI
  • CHD - Congenital Heart Disease
  • Surgery
04

Who can participate

Ages eligible
1 Day to 31 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All neonates (≤31 days) undergoing cardiac surgery with CPB for CHD will be deemed eligible for enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Failure to obtain from parent/guardian
  2. Clinical signs of preoperative persistent elevated pulmonary vascular resistance,
  3. Emergency surgery,
  4. Episode of cardiac arrest within 1 week before surgery,
  5. Recent treatment with and/or a condition that may require treatment with steroids (excluding steroid administration specifically for CPB),
  6. Use of inhaled NO (iNO) immediately prior to surgery,
  7. Structural renal abnormalities by ultrasound,
  8. Preoperative AKI,
  9. Use of other drugs,
  10. Weight less than \<2 kg,
  11. Gestational age \<36 weeks,
  12. Major extracardiac congenital anomalies,
  13. Non-English speakers.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Nitric Oxide

    Intraoperative NO entrained at 20 ppm into the oxygenator of the CPB circuit with standard care

    Drug: Nitric Oxide

  • Placebo comparator
    Oxygen

    Standard CPB without NO administered at any point intraoperatively

    Drug: Oxygen

Interventions

  • gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit

  • DrugOxygen

    Oxygen alone will be entrained for placebo arm

06

What researchers measure

Primary outcomes

  1. AKI

    Incidence of AKI in the first 72 hours postoperative as defined by the Kidney Disease Improving Global Outcomes (KDIGO) diagnostic classification

    Time frame: 72 hours

Secondary outcomes

  1. Biomarker evidence of AKI - NGAL

    Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker neutrophil gelatinase-associated lipocalin (NGAL)

    Time frame: 72 hours

  2. Biomarker evidence of AKI - KIM-1

    Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker kidney injury molecule-1 (KIM-1)

    Time frame: 72 hours

  3. Biomarker evidence of AKI - IL-18

    Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker interleukin-18 (IL-18)

    Time frame: 72 hours

  4. Biomarker evidence of AKI - L-FABP

    Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker liver-type fatty acid-binding protein (L-FABP)

    Time frame: 72 hours

  5. Biomarker evidence of AKI - urinary nitrite

    Incidence of structural AKI in the first 72 hours postoperative will be assessed by measurement of urine biomarker urinary nitrate.

    Time frame: 72 hours

  6. Impact on GFR

    Postoperative GFR measured using serum cystatin C.

    Time frame: 72 hours

  7. Low Cardiac Output

    Incidence of low cardiac output syndrome (LCOS) during the first 48 hours postoperative

    Time frame: 48 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Jan 3, 2020
StartActual
Jan 10, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04216927
Responsible party
Sponsor
First posted
Jan 3, 2020
Start date
Jan 10, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

David S Cooepr, MD
Contact
David.Cooper@cchmc.org
5138035448

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitric Oxide

Start the discussion